LAVA Therapeutics Announces Voluntary Delisting from Nasdaq
LAVA Therapeutics NV announced its voluntary delisting from Nasdaq, with trading suspended on November 21, 2025. Nasdaq filed a Form 25 with the SEC to remove the shares from listing. LAVA plans to terminate its reporting obligations by filing a Form 15 with the SEC around December 1, 2025. This information is for informational purposes only and not financial advice.
LAVA Therapeutics NV has announced its intention to voluntarily delist its shares from the Nasdaq Stock Market. Trading of the company’s shares was suspended prior to the opening of trading on November 21, 2025, and Nasdaq filed a Form 25 with the SEC to remove the shares from listing and registration. LAVA Therapeutics also plans to terminate its reporting obligations under the Securities Exchange Act by filing a Form 15 with the SEC on or about December 1, 2025. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. LAVA Therapeutics NV published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-114793), on November 21, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT) Original Document: here
